Analyst Arthur He CFA of H.C. Wainwright maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report), retaining the price target of $10.00.
Arthur He CFA’s rating is based on Prime Medicine, Inc.’s innovative approach to addressing significant unmet medical needs through its proprietary prime editing platform. The company recently announced a second liver program aimed at treating alpha-1 antitrypsin deficiency (AATD), a genetic disorder with no approved disease-modifying therapies currently available. This program targets the severe PiZZ genotype, affecting a substantial number of individuals in the U.S. and EU, which highlights the potential impact of their treatment.
Additionally, promising preclinical results have shown that their prime editing technology can effectively correct genetic mutations in a humanized mouse model, restoring normal protein levels. This evidence supports the potential for successful clinical outcomes, which could significantly enhance the company’s valuation. Arthur He CFA’s Buy rating reflects confidence in the company’s ability to leverage these scientific advancements and regulatory strategies to achieve future growth, supported by a risk-adjusted net present value analysis and a 12-month price target of $10 per share.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $10.00 price target.